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Abstract
Background: Tumor initiating stem-like cells (TISCs) are a subset of neoplastic cells that possess distinct survival
mechanisms and self-renewal characteristics crucial for tumor maintenance and propagation. The induction of
epithelial-mesenchymal-transition (EMT) by TGFb has been recently linked to the acquisition of TISC characteristics
in breast cancer. In HCC, a TISC and EMT phenotype correlates with a worse prognosis. In this work, our aim is to
elucidate the underlying mechanism by which cells acquire tumor initiating characteristics after EMT.
Methods: Gene and protein expression assays and Nanog-promoter luciferase reporter were utilized in epithelial
and mesenchymal phenotype liver cancer cell lines. EMT was analyzed with migration/invasion assays. TISC
characteristics were analyzed with tumor-sphere self-renewal and chemotherapy resistance assays. In vivo tumor
assay was performed to investigate the role of Snail1 in tumor initiation.
Conclusion: TGFb induced EMT in epithelial cells through the up-regulation of Snail1 in Smad-dependent
signaling. Mesenchymal liver cancer post-EMT demonstrates TISC characteristics such as tumor-sphere formation
but are not resistant to cytotoxic therapy. The inhibition of Snail1 in mesenchymal cells results in decreased Nanog
promoter luciferase activity and loss of self-renewal characteristics in vitro. These changes confirm the direct role of
Snail1 in some TISC traits. In vivo, the down-regulation of Snail1 reduced tumor growth but was not sufficient to
eliminate tumor initiation. In summary, TGFb induces EMT and TISC characteristics through Snail1 and Nanog up-
regulation. In mesenchymal cells post-EMT, Snail1 directly regulates Nanog expression, and loss of Snail1 regulates
tumor growth without affecting tumor initiation.
Background
Tumor initiating stem-like cells (TISCs), also defined as
cancer stem cells, are a subpopulation of neoplastic cells
that possess distinct survival and regeneration mechan-
isms important for chemotherapy resistance and disease
progression [1,2]. By definition, TISCs possess stem cell
features including resistance to apoptosis and self-
renewal [3-5]. After their initial discovery and character-
ization within hematological malignancies [6,7], TISCs
have now been described in many different malignancies
including hepatocellular carcinoma (HCC) [8,9]. Further
evidence supports that HCC arises as a direct conse-
quence of dysregulated proliferation of hepatic
progenitor cells [10,11]. Transcriptome analysis of HCC
demonstrated that a progenitor-based (TISC-phenotype)
expression profile is associated with a poor prognosis
compared to differentiated tumors (hepatocyte-pheno-
type) [12-14].
Resistance to therapy and metastatic disease are two
factors that correlate a TISC-phenotype HCC with poor
survival. TISCs are hypothesized to be the source of
metastatic lesions, as a tumor-initiating cell [15].
Although this hypothesis remains controversial, recent
work establishes a connection between epithelial-
mesenchymal-transition (EMT) and a TISC-phenotype
[16,17]. EMT is a critical developmental process that
plays a central role in the formation and differentiation
of multiple tissues and organs. During EMT, epithelial
cells lose cell-cell adhesion and apical-polarity, and
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ness, and resistance to apoptosis [18].
One of the key hallmarks of EMT is loss of E-cad-
herin, a cell-adhesion protein that is regulated by multi-
ple transcription factors including Snail, Slug, and Twist.
These transcription factors act as E-box repressors and
block E-cadherin transcription [18]. In cancer biology,
EMT is one mechanism to explain the invasive and
migratory capabilities that epithelial carcinomas acquire
during metastasis [19,20]. In HCC, increased expression
of the E-cadherin repressors Twist and Snail correlates
with poor clinical outcomes [21]. In breast cancer, EMT
is associated with the acquisition of a TISC CD44
+/CD24
low phenotype [17,22].
One of the major inducer of EMT is transforming
growth factor-b (TGFb), a multifunctional cytokine that
regulates cell proliferation, differentiation and apoptosis
[23]. In early stages of carcinogenesis, TGFb serves as a
tumor suppressor by inhibiting cell growth, and in later
stages of disease, tumor cells escape this growth inhibi-
tion. As late stage cancer tends to be resistant to TGFb-
driven growth arrest signals and as TGFb is a known
inducer of EMT, TGFb is proposed to be a facilitator of
cancer progression during late stage disease [24-26].
TGFb induces EMT by up-regulating Snail1 via the
Smad-dependent pathways [27]. Mishra and colleagues
have reviewed the complexity of TGFb signaling during
hepatocarcinogenesis, specifically as related to b2-Spec-
trin loss and stem cell malignant transformation
[15,28-30].
As additional evidence linking EMT to TISCs, TGFb
regulates Nanog expression, a transcription factor that
contributes to self-renewal and cell fate determination
in embryonic stem cells [31,32]. In prostate cancer,
increased Nanog expression is implicated in tumor pro-
gression, and the co-expression of Nanog and Oct4 pro-
motes tumor-sphere formation [4,33,34]. In colon
cancer, increased Snail1 expression correlates to
increased Nanog expression [35]. In human HCC cell
lines, TGFb regulates CD133 expression, a marker of
TISCs, through induction of epigenetic modifications of
the CD133 promoter [23,36].
Thus, several studies haved e m o n s t r a t e dt h a tT G F b
drives EMT through Snail1 up-regulation, and other stu-
dies have correlated EMT to the acquisition of TISC
characteristics. What is lacking is an understanding of
the mechanism of how liver cancer cells acquire TISC
characteristics through EMT. Our hypothesis is that
mesenchymal cells acquire TISC traits after EMT
through Snail1-dependent mechanisms. In this report,
we demonstrate that mesenchymal liver cancer cells
(post-EMT) possess several TISC characteristics com-
pared to epithelial cells. TGFb induces EMT and TISC
characteristics in epithelial cells through Snail1.I n
mesenchymal cells, knock-down of Snail1 results in loss
of Nanog and reduction of TISC traits. In vivo studies
demonstrate that Snail1 regulates tumor growth but
does not fully control tumor initiation.
Methods
Cell Culture
Epithelial and mesenchymal murine liver cancer cells
were cultured in Dulbecco’s modified Eagle’sm e d i u m
(DMEM)/F12 (Sigma) supplemented with 10% fetal
bovine serum as described [37]. The human HCC cell
line Huh7 was provided by Jianming Huh, Penn State
College of Medicine and cultured as described [36,38].
The human HCC The human HCC cell lines MHCC97-
L were provided by Xinwei Wang, National Cancer
Institute, under agreement with the Liver Cancer Insti-
tute, Zhongshan Hospital, Fudan University, Shanghai,
China and cultured as described [39].
Transfections
For Snail1 transient knockdown, cells were transfected
with 100 pM of Snail1 Stealth siRNA (Invitrogen) using
Lipofectamine 2000 (Invitrogen). For Smad signaling
inhibition, cells were transfected with 2 ug of DNA
using Fugene 6 (Roche). To generate Snail1 knockdown
stable transfectants, mesenchymal cells were transfected
with Snail1 Mission shRNA lentivirus (Sigma) and
selected with 2 ug/ml of puromycin.
Luciferase Assay
pCMV5-Smad7-HA (Plasmid 11733), pRK-Smad3ΔC
(Plasmid 12626), and Nanog-Luc (Plasmid 16337) were
provided by Addgene. Cells were plated in 12 well
plates, incubated overnight, and transfected with the
Nanog-Luc plasmid and Renilla for 24 hours (4:1 Nanog-
Luc:Renilla ratio). Cells were washed with 1 × PBS,
serum free starved for 2 hours, and treated with 5 ng/
ml of TGFb for 24 hours. Following cell lysis, luciferase
activity was measured using the Dual Luciferase Assay
Kit (Promega) and a Sirius Luminometer V3.1 (Zylux).
Luciferase reading light units (RLU) were normalized to
Renilla RLU and a fold change was calculated.
qRT-PCR
Trizol (Invitrogen) was used to isolate total RNA from
cells according to manufacturer’s protocol. Isolated
RNA was quantified using the ND-1000 spectrophot-
ometer (NanoDrop) and complementary single strand
DNA was synthesized using the Omniscript RT Kit
according to the manufacturers protocol (Qiagen). qPCR
was performed using Taqman Gene Expression Assays
and ABI-Prism 7700 Thermal Cycler (Applied Biosys-
tems). Normalization was performed using b-actin or
Gapdh as an endogenous control and relative gene
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(-ΔΔCt)
method with SDS 2.2.2 software [36].
Cell Viability Assays
Cell viability was performed using the XTT (2,3-bis(2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-car-
boxanilide) kit (Trevigen) according to the manufac-
turer’sp r o t o c o l .5×1 0
3 cells were plated in 96-well
plates, incubated for 24 hours at 37°C, and treated with
specified agents at defined time points.
Western Blot Analysis
Cells were washed twice with ice cold 1XPBS and cell
lysates were harvested by the addition of lysis buffer (40
nM Tris [pH 7.4], 150 mM NaCl, 10 mM ethylene dia-
mine tetraccetic acid, 10% glycerol, 1% Triton X-100, 10
mM glycerophosphate, 1 mM Na3VO4, 1 mM phenyl-
methylsulfonyl fluoride) supplemented with protease
inhibitor cocktail tablets (Roche). BCA protein assay
(Thermo Fisher Scientific) was used to determine pro-
tein concentration as described [40]. 30 ug of protein
lysates were separated on a NuPAGE 4-12% Bis-Tris
Gel (Invitrogen) and the separated proteins were trans-
ferred onto a polyvinylidene difluoride membrane (Invi-
trogen). After blocking for 60 min with 5% non-fat dry
milk, membranes were incubated with the primary anti-
body overnight at 4°C followed by incubation with cor-
responding secondary antibody for 60 min at room
temperature. The membranes were developed using
enhance chemiluminescence solutions (Thermo Fisher
Scientific) [41].
Cell Migration Assay
The capability of tumor cell migration was assessed
using a wound-healing assay. Confluent cell monolayers
were manually wounded by scraping the cells with a
1,000 μL pipette tip down the center of the well. The
cell culture medium was replaced and migration was
assessed at 24 hours [37].
Matrigel Invasion Assay
Cell invasion was assessed using 6-well Transwell perme-
able inserts with 8-μm pores (Corning) [37]. In brief, 1 ×
10
5 cells were cultured in a serum-free DMEM/F12 med-
ium in an insert coated with Matrigel (BD). Below the
insert, the chamber of 6-well plates contained DMEM/
F12 supplemented with 10% FBS. Cells were incubated in
a 37°C incubator for 48 hours and the number of cells
that invaded across the membranes and fallen onto the
bottom of the plate was counted.
Transcriptome analysis
Using the cell lines from the liver specific Pten
-/- model
described [37] P2E (epithelial) and P2M (mesenchymal)
messenger RNA were analyzed using an Illumina mouse
gene chip according to the manufacturer’sp r o t o c o la n d
as described [37]. Housekeeping genes were used as
standards to generate expression levels, and data analysis
was conducted using 1.4-fold or greater change in
expression with p < 0.05 as significant. The full comple-
ment of the expression data is available at http://www.
ncbi.nlm.nih.gov/geo (Accession number GSE18255).
Spheroid Formation Assay
The capability of self-renewal was assessed using Corn-
ing Ultra-Low Attachment Surface (Corning). 5 × 10
3
cells were seeded and incubated in a cell culture incuba-
tor for 1 week in DMEM/F12 supplemented with 10%
FBS or serum free medium and phase-contrast images
were obtained.
In vivo tumor growth assay
Cells were counted with trypan blue exclusion and sus-
pended in a 1:3 dilution of Matrigel (Matrigel:DMEM/
F12 supplemented with 10% FBS) [36]. 1 × 10
4 and 1 ×
10
5 cells/50 μLw e r ei n j e c t e ds u b c u t a n e o u s l yi n t o1 0 -
week-old nude mice. Caliper measurements of tumor
volume (length × width × height) were conducted every
2 days. After 3 weeks, mice were sacrificed for tumor
analysis. All procedures were in compliance with our
institution’s guidelines for the use of laboratory animals
and approved by the Penn State College of Medicine
Institutional Animal Care and Use Committee.
Statistical Analysis
Microarray statistical analysis was performed as describe
[37]. Student t test was used comparing two groups.
One-way ANOVA was used comparing multiple groups
followed by Tukeys post-hoc test. All analysis with a p <
0.05 was considered significant.
Results
Mesenchymal cells acquire TISC characteristics post-EMT
In a previous report, we established a model of EMT
using liver cancer cell lines derived from Pten
-/- mice
[37]. In this model, we transplanted epithelial liver can-
cer cells, and from the resulting tumors, harvested
epithelial and mesenchymal cells. The epithelial tumor
cells were identical to parent cells, labeled P2-Epithelial
(P2E), and the mesenchymal, fibroblastoid cells, were
labeled P2-Mesenchymal (P2M) (Figure 1A). Both
epithelial and mesenchymal cells demonstrated Pten
-/-
genotype [37]. In support of the EMT-metastasis para-
digm, mesenchymal cells demonstrated significant meta-
static potential [37]. To confirm the persistence of
epithelial and mesenchymal phenotypes, we analyzed the
expression of key EMT genes and migratory/invasion in
vitro. The mesenchymal cells demonstrate loss of E-
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and Zeb2, significant migration in wound assay, and
increased invasion through Matrigel pores compared to
epithelial cells (Figure 1B-E).
In mesenchymal cells, transcriptome profiling demon-
strated increased expression of multiple liver TISC mar-
kers (Figure 2A). Real-time PCR validated up-regulated
Nanog, Oct-4, CD44,a n dEpCam (Figure 2B). Although
CD133 is a strong TISC marker in previous reports, the
mesenchymal cells have no detectable CD133 expres-
sion, making comparative analysis impossible. In terms
of self-renewal assay, the mesenchymal cells were able
to form large tumor-spheres in low adherent plates (Fig-
ure 2C). Increased stem cell markers and tumor-sphere
formation indicates that the mesenchymal cells have a
TISC phenotype.
Resistance to chemotherapy is linked to cell proliferation
To test the hypothesis that mesenchymal cells are resis-
tant to chemotherapy, a TISC feature, cells were treated
with doxorubicin and 5’Fluorouracil. The mesenchymal
cells demonstrate increased sensitivity to genotoxic
agents compared to epithelial cells (Figure 3A-B). In
terms of cell cycle progression, the mesenchymal cells
are highly proliferative compared to the epithelial cells
(Figure 3E). Thus, we conclude that resistance to che-
motherapy is linked to the level of cell proliferation, not
mesenchymal status, consistent with the mechanism of
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Figure 1 Murine epithelial and mesenchymal liver cancer cells. (A) Representative phase-contrast images (10 × magnification) of epithelial
and mesenchymal cells. (B) Heatmap of mesenchymal markers generated from raw microarray values. (C) Relative expression of mRNAs
endcoding E-cadherin, Snail1, Zeb1 and Zeb2 normalized to endogenous control Gapdh. Bars represent mean ± SEM of triplicates, *p < 0.01.
Western blot analysis of E-cadherin, Snail1, and b-actin. Data representative of two independent experiments. (D) Wound healing assay. Bars
represents mean ± SEM of triplicates, *p < 0.01. (E) Matrigel invasion assay. Phase-contrast images (4 × magnification) of cells that have invaded
the membrane and adhered to the bottom of the plate. Data are expressed as the total number of invasive cells at the bottom of the plate,
with five fields counted per well, n = 3 wells/cell line, and reported as the mean ± SEM, *p < 0.01.
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Page 4 of 13action of cytotoxic agents. In addition to rate of prolif-
eration, Abcg2 expression correlated with chemotherapy
resistance (Figure 3A &3B, 2B), indicating that drug
resistance may be dependent on the ATP-binding cas-
sette expression as a mechanism of drug efflux. ATP-
binding cassette efflux has been highly correlated to
epithelial phenotype liver TISCs [14,42].
In addition to resistance to genotoxic agents, we
assessed whether the mesenchymal cells are resistant to
TRAIL-induced and TGFb-induced apoptosis. Although
there was no significant difference in response to TRAIL
stimulation (Figure 3C), the mesenchymal cells demon-
strate resistance to TGFb-induced apoptosis (Figure
3D), a characteristic of TISCs [40].
TGFb-induced EMT results in TISC characteristics
During later stages of disease, TGFb induces EMT and
contributes to disease progression [15,43]. After TGFb
stimulation, epithelial cells undergo a morphological
change from cuboidal to fibroblastic-like cells (Figure
4A). In addition to morphology change, TGFb
treatment resulted in increased cell migration and the
formation of larger spheroids in low adherent plates
(Figure 4B &4C. This TGFb-induced change was asso-
ciated with typical EMT characteristics, including
decreased E-cadherin and increased Snail1 and Nanog
(Figure 4D &4E).
Inhibition of Snail1 blocks TISC characteristics
In HCC, a TISC phenotype with Snail1 over-expression
is associated with poor prognosis [21]. To test the speci-
fic role of Snail1 in up-regulating TISC characteristics,
we utilized siRNA to knock down Snail1 in mesenchy-
mal cells. After Snail1 siRNA treatment, TISC markers
Nanog and CD44 decreased significantly (Figure 5A),
which was associated with decreased spheroid formation
(Figure 5B) and decreased migration (Figure 5C).
TGFb regulates Snail and Nanog through Smad signaling
The primary mechanism of TGFb-induced EMT is
through Smad-dependent signaling. Following activation
of TGFb receptors, Smad2 and Smad3 are
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Page 5 of 13phosphorylated and form the Smad2/3/4 heterocomplex,
which translocates to the nucleus to regulate Snail1
transcription [19,27,44]. After TGFb stimulation in
epithelial cells, Snail1 increased (Figure 4D). In order to
c o n f i r mt h a tT G F b induces Snail1 through Smad-
dependent pathways in our model, we utilized inhibitory
Smads, Smad7 and dominant-negative Smad3 (ΔSmad3),
which block heterocomplex formation. Epithelial cells
were transfected with Smad7 or ΔSmad3 vectors 24
hours prior to TGFb stimulation. qPCR and western
blot analysis demonstrated that inhibitory Smads signifi-
cantly attenuated TGFb-induced Snail1 up-regulation
(Figure 6A &6B).
TGFb regulates Nanog promoter activity through
Smad signaling in human embryonic stem cells [31]. To
confirm that TGFb can induce Nanog promoter activity
in our model, epithelial cells were co-transfected with
Nanog-Luc and Smad7 or ΔSmad3 vectors. Following
TGFb stimulation, Nanog-Luc activity was significantly
attenuated by inhibitory Smads (Figure 6C &6D), indi-
cating that TGFb stimulates Nanog promoter activity
through Smad-dependent signaling.
Snail1 directly regulates Nanog promoter
After transient knock-down of Snail1, Nanog expression
is decreased, indicating that Snail1 directly regulates
TISC genes in mesenchymal cells (Figure 3B). To
further investigate this Snail1-driven TISC expression
profile, we established stable Snail1 knock-down in
mesenchymal-Snail1-shRNA cells (Figure 7A). In these
mesenchymal-Snail1-shRNA cells, down regulation of
Snail1 corresponded to decreased Nanog promoter
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Page 6 of 13activity and decreased Nanog and CD44 expression (Fig-
ure 7A &7B).
Inhibition of Snail1 results in decreased tumor growth in
vivo
As demonstrated, Snail1 is a key regulator of TISC charac-
teristics in vitro. To investigate the role of Snail1 in tumor
initiation, we inoculated 1 × 10
4 mesenchymal-Snail1-
shRNA cells into nude mice. The mesenchymal-Snail1-
shRNA cells demonstrate reduced in tumor growth com-
pared to control mesenchymal cells. Analysis of tumors
demonstrates that Snail1 expression was down-regulated
in 1 × 10
4 cell initiated tumors from mesenchymal-Snail1-
siR cells (Figure 7C). However, tumor initiation was not
affected by Snail1 suppression, as evidence by all inocula-
tions forming tumors, even in Snail1 inhibited cells.
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In order to investigate SNAIL1 and NANOG expression
in human HCC cells, we utilized Huh7 and MHCC97-L
cells. Huh7 cells have been described to be epithelial
whereas MHCC97-L cells are mesenchymal with meta-
static potential [38,39]. Accordingly, MHCC97-L cells
demonstrate significant migration and invasion,
increased expression of SNAIL1, NANOG and decreased
expression of E-Cadherin (Figure 8B-D). Mesenchymal
MHCC97-L cells also demonstrate TISC characteristics
including increased NANOG, BMI-1, CD44 and OCT4
mRNA expression as well as increased tumorsphere for-
mation (Figure 8E &8F).
Discussion
Although liver transplantation has significantly improved
survival in patients with early stage HCC, the prognosis
for late stage HCC remains poor [45]. Causes of poor
prognosis in late stage disease include invasive/
metastatic disease and tumor recurrence after treatment.
In breast cancer, EMT has been linked to TISC charac-
teristics and resistant disease. Although this link
between EMT and TISCs has been established in other
cancers, including breast, prostate, nasopharyngeal, and
colon cancer, this relationship has yet to be defined in
HCC [17,22,46]. One potential link between EMT and
TISCs in liver cancer is TGFb.
TGFb has a dual role in HCC either as a tumor sup-
pressor in early stages or tumor promoter in later stages
[15,43]. One of the mechanisms of early neoplastic
transformation is through the evasion of cytostatic
effects of TGFb [43]. During the late stages of HCC
tumorgenesis, TGFb stimulates cellular invasion through
the EMT program [44].
TGFb induces EMT through Snail1, which represses
E-cadherin by binding to E-box promoter elements
[18,19,47]. In cancer patients, an EMT-phenotype tran-
scriptome profile, with increased Snail1 expression,
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Page 8 of 13correlates with invasive tumors [21,48,49]. In this report,
TGFb stimulation of epithelial liver cancer cells results
in a mesenchymal phenotype with fibroblastoid appear-
ance, loss of E-cadherin, increased invasion and migra-
tion, and an up-regulation of Snail1. In addition, TGFb
treatment induces a TISC phenotype in epithelial cells.
Although TGFb-induced EMT generates TISC charac-
teristics [17,22], the underlying mechanism has not yet
been elucidated. Based on our results, we hypothesize
that these TISC characteristics are Snail1 dependent.
Inhibition of Snail1 causes the down-regulation of
Nanog, Bmi-1 and CD44, loss of a migration and self-
renewal as evidenced by decreased tumor-sphere
formation.
Another key regulatory signaling pathway known to
induce EMT in liver cells is the Hedgehog (Hh) signal-
ing pathway. Hh promotes EMT in response to chronic
liver injury [50]. In addition, Hh signaling has been sug-
gested to play an important role in the maintenance of
TISCs, and BMI-1, the polycomb group protein, may
directly mediate Hh signaling in order to confer a self-
renewal capacity in TISCs [10,46,51]. However, within
our system, we were unable to see significant differences
of BMI-1 between epithelial and mesenchymal cells.
TGFb also directly controls Nanog in human embryo-
nic stem cells [31]. Nanog is a key transcription factor
that regulates self-renewal in stem cells [4,52]. Recent
studies demonstrate that Nanog promotes TISC charac-
teristics, and the down regulation of Nanog inhibits
sphere formation and tumor development [4,34,35,53].
In this report, Nanog is up-regulated by TGFb through
Smad signaling. In addition, Snail1 directly regulates
Nanog promoter activity.
TISCs are proposed to initiate tumors. In our model,
liver cancer cells with a mesenchymal phenotype
demonstrate TISCs characteristics, including tumor-
sphere formation and increased expression of CD44 and
Nanog. We further investigated epithelial and
C
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Page 9 of 13mesenchymal phenotypes in human HCC, Huh7 and
MHCC97-L cells. Accordingly, Huh7 cells follow an
epithelial phenotype whereas MHCC97-L cells are more
mesenchymal demonstrating increased Snail1, Zeb1,
Zeb2 mRNA expression, decreased E-cadherin expres-
sion, increased migration/invasion and increased tumor-
sphere formation [38].
In our murine system, Snail1 inhibition resulted in
loss of tumor-sphere formation, decreased expression of
CD44 and Nanog, and decreased tumor growth. Accord-
ing to our in vitro results, Snail1 clearly regulates TISC
characteristics. However, the loss of Snail1 is not suffi-
cient to inhibit tumor initiation, as evidenced by in vivo
results. These findings are not un-expected in that the
proposed TISC-driven tumor initiation is an early event
in tumorigenesis, and cells that acquire TISC character-
istics after EMT are a late event in tumor progression.
In addition, Snail1 is one of many regulators of EMT,
and thus manipulation of multiple factors may be
required to fully inhibit tumor initiation.
Conclusion
In summary, we demonstrated that TGFb induces EMT
and TISC characteristics through the up-regulation of
Snail1 and Nanog. In addition, Snail1 directly regulates
Nanog promoter activity. Notably, expression of both
B A
R
e
l
a
t
i
v
e
 
N
a
n
o
g
 
L
u
c
i
f
e
r
a
s
e
 
A
c
t
i
v
i
t
y
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Snail1 Nanog CD44
0.0
0.2
0.4
0.6
0.8
1.0
1.2
*
*
*
S
c
r
a
m
b
l
e
d
S
n
a
i
l
1
E-Actin
Snail1
R
e
l
a
t
i
v
e
 
m
R
N
A
 
E
x
p
r
e
s
s
i
o
n
Scrambled
Snail1
C  
Scrambled Snail1
Scrambled
R
e
l
a
t
i
v
e
 
S
n
a
i
l
1
 
m
R
N
A
 
E
x
p
r
e
s
s
i
o
n
 
0.5
1.0
1.5
0
0.5
1.0
1.5
R
e
l
a
t
i
v
e
 
S
n
a
i
l
1
 
m
R
N
A
 
E
x
p
r
e
s
s
i
o
n
 
0
Scrambled
1X104 Cells 1X105 Cells
T
u
m
o
r
 
V
o
l
u
m
e
 
(
m
m
3
)
Days 5 9 13 17 21
0
200
400
600
800
*
Scrambled
Snail1
0
200
400
600
800
1000
1200
1400
T
u
m
o
r
 
V
o
l
u
m
e
 
(
m
m
3
)
Scrambled
Snail1 
Days5 9 1 3 1 7 2 1
Snail1 
*
Snail1 
*
*
Figure 7 Repression of Snail1 attenuates Nanog promoter activity and tumor proliferation. (A) Relative gene expression of Snail1, Nanog,
and CD44 of mesenchymal-scrambled-shRNA compared to mesenchymal-Snail1-shRNA cells. Bars represent mean ± SEM of triplicates, *p < 0.05.
Western blot of Snail1 and b-actin, with blots representative of two independent experiments. (B) Inhibition of Snail1 reduces Nanog luciferase
activity. Data presented are shown as mean ± SEM of three independent experiments, *p < 0.05. (C) Tumors of indicated number of cells of
mesenchymal-scrambled-shRNA or mesenchymal-Snail1-shRNA knock-down cells. Tumor volume reported as mean ± SEM, *p < 0.05; N = 4/
group. Relative Snail1 mRNA expression of tumor tissues. Data presented are reported as mean ± SEM of all Scrambled and Snail1 tumor tissues,
*p < 0.05; N = 4/group.
Dang et al. BMC Cancer 2011, 11:396
http://www.biomedcentral.com/1471-2407/11/396
Page 10 of 13SNAIL1 and NANOG is higher in human mesenchymal
cells. Inhibition of Snail1 alone is not sufficient to inhi-
bit tumor initiation, but does result in reduction of
tumor growth in vivo.
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